Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors

Thehang Luu, Warren Chow, Dean Lim, Marianna Koczywas, Paul Frankel, Mihaela Cristea, Kim Margolin, James H. Doroshow, George Somlo, Shikha Gaur, Yun Yen, Robert J. Morgan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Bortezomib demonstrates synergism with gemcitabine via a fixed-dose rate (FDR). The aim of this phase I trial in solid tumors was to establish the maximum tolerated dose (MTD) and safety data for this combination. Patients and Methods: Twenty-nine patients with a median age of 63 (range 36-84) years and median Karnofsky Performance Status of 90 (range 60-100) were enrolled and treated with bortezomib (1.0 or 1.3 mg/m2) on days 1, 4, 8 and 11 and FDR gemcitabine (750, 1,000, or 1,250 mg/m2) on days 1 and 8 of each 21-day cycle. Response was evaluated every two cycles. Results: Dose-limiting toxicities were grade 4 thrombocytopenia and neutropenia and grade 3 liver function test abnormalities. The MTD was bortezomib 1 mg/m2 and FDR gemcitabine 1,250 mg/m2. The median number of cycles delivered was 3 (range 1-28). There was one partial response and six cases of stable disease. The median duration of response was 8.5 (range 3-20) months. Conclusion: FDR gemcitabine and bortezomib combination can be delivered effectively with acceptable toxicity.

Original languageEnglish
Pages (from-to)167-174
Number of pages8
JournalAnticancer Research
Volume30
Issue number1
Publication statusPublished - Jan 1 2010
Externally publishedYes

Fingerprint

gemcitabine
Maximum Tolerated Dose
Neoplasms
Karnofsky Performance Status
Liver Function Tests
Neutropenia
Safety
Bortezomib

Keywords

  • Bortezomib
  • Fixed-dose rate gemcitabine
  • Phase I
  • Solid tumors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Luu, T., Chow, W., Lim, D., Koczywas, M., Frankel, P., Cristea, M., ... Morgan, R. J. (2010). Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. Anticancer Research, 30(1), 167-174.

Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. / Luu, Thehang; Chow, Warren; Lim, Dean; Koczywas, Marianna; Frankel, Paul; Cristea, Mihaela; Margolin, Kim; Doroshow, James H.; Somlo, George; Gaur, Shikha; Yen, Yun; Morgan, Robert J.

In: Anticancer Research, Vol. 30, No. 1, 01.01.2010, p. 167-174.

Research output: Contribution to journalArticle

Luu, T, Chow, W, Lim, D, Koczywas, M, Frankel, P, Cristea, M, Margolin, K, Doroshow, JH, Somlo, G, Gaur, S, Yen, Y & Morgan, RJ 2010, 'Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors', Anticancer Research, vol. 30, no. 1, pp. 167-174.
Luu T, Chow W, Lim D, Koczywas M, Frankel P, Cristea M et al. Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. Anticancer Research. 2010 Jan 1;30(1):167-174.
Luu, Thehang ; Chow, Warren ; Lim, Dean ; Koczywas, Marianna ; Frankel, Paul ; Cristea, Mihaela ; Margolin, Kim ; Doroshow, James H. ; Somlo, George ; Gaur, Shikha ; Yen, Yun ; Morgan, Robert J. / Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. In: Anticancer Research. 2010 ; Vol. 30, No. 1. pp. 167-174.
@article{d49f8bd55849481aa411dc13573c59b3,
title = "Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors",
abstract = "Background: Bortezomib demonstrates synergism with gemcitabine via a fixed-dose rate (FDR). The aim of this phase I trial in solid tumors was to establish the maximum tolerated dose (MTD) and safety data for this combination. Patients and Methods: Twenty-nine patients with a median age of 63 (range 36-84) years and median Karnofsky Performance Status of 90 (range 60-100) were enrolled and treated with bortezomib (1.0 or 1.3 mg/m2) on days 1, 4, 8 and 11 and FDR gemcitabine (750, 1,000, or 1,250 mg/m2) on days 1 and 8 of each 21-day cycle. Response was evaluated every two cycles. Results: Dose-limiting toxicities were grade 4 thrombocytopenia and neutropenia and grade 3 liver function test abnormalities. The MTD was bortezomib 1 mg/m2 and FDR gemcitabine 1,250 mg/m2. The median number of cycles delivered was 3 (range 1-28). There was one partial response and six cases of stable disease. The median duration of response was 8.5 (range 3-20) months. Conclusion: FDR gemcitabine and bortezomib combination can be delivered effectively with acceptable toxicity.",
keywords = "Bortezomib, Fixed-dose rate gemcitabine, Phase I, Solid tumors",
author = "Thehang Luu and Warren Chow and Dean Lim and Marianna Koczywas and Paul Frankel and Mihaela Cristea and Kim Margolin and Doroshow, {James H.} and George Somlo and Shikha Gaur and Yun Yen and Morgan, {Robert J.}",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "30",
pages = "167--174",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors

AU - Luu, Thehang

AU - Chow, Warren

AU - Lim, Dean

AU - Koczywas, Marianna

AU - Frankel, Paul

AU - Cristea, Mihaela

AU - Margolin, Kim

AU - Doroshow, James H.

AU - Somlo, George

AU - Gaur, Shikha

AU - Yen, Yun

AU - Morgan, Robert J.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Bortezomib demonstrates synergism with gemcitabine via a fixed-dose rate (FDR). The aim of this phase I trial in solid tumors was to establish the maximum tolerated dose (MTD) and safety data for this combination. Patients and Methods: Twenty-nine patients with a median age of 63 (range 36-84) years and median Karnofsky Performance Status of 90 (range 60-100) were enrolled and treated with bortezomib (1.0 or 1.3 mg/m2) on days 1, 4, 8 and 11 and FDR gemcitabine (750, 1,000, or 1,250 mg/m2) on days 1 and 8 of each 21-day cycle. Response was evaluated every two cycles. Results: Dose-limiting toxicities were grade 4 thrombocytopenia and neutropenia and grade 3 liver function test abnormalities. The MTD was bortezomib 1 mg/m2 and FDR gemcitabine 1,250 mg/m2. The median number of cycles delivered was 3 (range 1-28). There was one partial response and six cases of stable disease. The median duration of response was 8.5 (range 3-20) months. Conclusion: FDR gemcitabine and bortezomib combination can be delivered effectively with acceptable toxicity.

AB - Background: Bortezomib demonstrates synergism with gemcitabine via a fixed-dose rate (FDR). The aim of this phase I trial in solid tumors was to establish the maximum tolerated dose (MTD) and safety data for this combination. Patients and Methods: Twenty-nine patients with a median age of 63 (range 36-84) years and median Karnofsky Performance Status of 90 (range 60-100) were enrolled and treated with bortezomib (1.0 or 1.3 mg/m2) on days 1, 4, 8 and 11 and FDR gemcitabine (750, 1,000, or 1,250 mg/m2) on days 1 and 8 of each 21-day cycle. Response was evaluated every two cycles. Results: Dose-limiting toxicities were grade 4 thrombocytopenia and neutropenia and grade 3 liver function test abnormalities. The MTD was bortezomib 1 mg/m2 and FDR gemcitabine 1,250 mg/m2. The median number of cycles delivered was 3 (range 1-28). There was one partial response and six cases of stable disease. The median duration of response was 8.5 (range 3-20) months. Conclusion: FDR gemcitabine and bortezomib combination can be delivered effectively with acceptable toxicity.

KW - Bortezomib

KW - Fixed-dose rate gemcitabine

KW - Phase I

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=77649241460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649241460&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 167

EP - 174

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -